Publications - IR Sant Pau

Search

01/06/2026 A multicenter prospective evaluation of the benefits of Dexcom ONE plus in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study

Chico, A, Aguilera-Hurtado, E, Albareda, M, Moreno-Fernández, J, Beato-Vibora, P, Fernández-Rubio, E, Cuesta, M, Bartual, A, Ampudia-Blasco, FJ, Bandrés, O, Ares, J, Rivero, MT, Picón-César, MJ. A multicenter prospective evaluation of the benefits of Dexcom ONE plus in subjects with type 2 diabetes on insulin therapy beyond glycemic control: results from the LIFE-ONE study. ACTA DIABETOLOGICA. 2026; 63(6)DOI:10.1007/s00592-026-02682-9. PMID:41964691. IF:2.900(Q3/6D).

01/06/2026 Assessing Europe's policy readiness to confront the MASLD/MASH public health threat

Lazarus, JV, White, TM, Agirre-Garrido, L, Abeysekera, KWM, Brennan, PN, Bruha, R, Buttigieg, S, Carrieri, P, Cortez-Pinto, H, Flisiak, R, Francque, SMA, Frühbeck, G, Gheorghe, LS, Hagström, H, Holleboom, AG, Ivanov, K, Jensterle, M, Jepsen, P, Kupcinskas, J, Mark, HE, Mauricio, D, Bibi, SM, Moreno, C, Mrzljak, A, Papanicolaou, E, Papp, M, Papatheodoridis, G, Peck-Radosavljevic, M, Pugliese, N, Ryan, JD, Ribeiro, RT, Salupere, R, Skladany, L, Tolmane, I, Yki-Järvinen, H, Schattenberg, JM, Pericàs, JM. Assessing Europe's policy readiness to confront the MASLD/MASH public health threat. Lancet Regional Health-Europe. 2026; 65DOI:10.1016/j.lanepe.2026.101713. PMID:42266904. IF:13.000(Q1/1D).

01/06/2026 Prevalence and clinical characteristics of erectile dysfunction among men with type 2 diabetes in primary care: A cross-sectional study in Catalonia

Martinez-Mores, S, Fillat, MBV, Vlacho, B, Navas, E, Fernandez-Camins, B, Franch-Nadal, J, Mauricio, D. Prevalence and clinical characteristics of erectile dysfunction among men with type 2 diabetes in primary care: A cross-sectional study in Catalonia. Primary Care Diabetes. 2026; 20(3)DOI:10.1016/j.pcd.2026.04.006. PMID:42000296. IF:2.300(Q2/5D).

01/06/2026 Clinical trends in Catalonia's Primary Care Setting (2018-2023) in Elderly (=75 years) and Frail Adults with Type 2 Diabetes

Ramon-Granés, M, Fernàndez-Camins, B, Lapena-Estella, C, Orfila-Pernas, F, de la Puente, JB, Vlacho, B, Mauricio, D, Navas-Méndez, E, Franch-Nadal, J. Clinical trends in Catalonia's Primary Care Setting (2018-2023) in Elderly (=75 years) and Frail Adults with Type 2 Diabetes. Primary Care Diabetes. 2026; 20(3)DOI:10.1016/j.pcd.2026.03.010. PMID:41916804. IF:2.300(Q2/5D).

01/06/2026 Glucocorticoid-Induced Positive Feedback in Cushing Disease: Insights From a Spanish Multicenter Cohort

Biagetti, B, Cardona-Arias, A, Soto-Moreno, A, García, MDO, Rodríguez, MDM, Gonzalez-Fernandez, L, Castro, A, Guerrero-Pérez, F, Iglesias, P, Camara, R, Paja, M, Lázaro, VA, Simo-Servat, A, Lozano-Aida, C, Echarri, AI, Valero, LM, Villar-Taibo, R, Bernabéu, I, Fajardo-Montañana, C, Aulinas, A, García-Centeno, R, Hanzu, F, Araujo-Castro, M. Glucocorticoid-Induced Positive Feedback in Cushing Disease: Insights From a Spanish Multicenter Cohort. Endocrine Practice. 2026; 32(6)DOI:10.1016/j.eprac.2025.12.013. PMID:41443540. IF:4.600(Q1/3D).

01/06/2026 Endovascular Interventions Reduce Rebleeding in Patients With Gastric Varices: An Individual Patient Data Meta-Analysis

Biswas, S, Aggarwal, A, Lo, GH, Luo, XF, Yang, L, Escorsell, A, Mehta, S, Swaroop, S, Agarwal, S, Agarwal, A, Saxena, S, Mishra, AK, Tripathi, S, Gunjan, D, Gamanagatti, S, Shalimar. Endovascular Interventions Reduce Rebleeding in Patients With Gastric Varices: An Individual Patient Data Meta-Analysis. Clinical Gastroenterology and Hepatology. 2026; 24(6)DOI:10.1016/j.cgh.2026.01.002. PMID:41539349. IF:12.000(Q1/1D).

01/06/2026 Prevalence and characteristics of subclinical polymyalgia rheumatica in patients with giant cell arteritis

Narváez, J, Sirvent, E, Sánchez-Rodríguez, I, Sabaté-Llobera, A, Cortés-Romera, M, Moya-Alvarado, P, Rozadilla, A, Reina, D. Prevalence and characteristics of subclinical polymyalgia rheumatica in patients with giant cell arteritis. RHEUMATOLOGY. 2026; 65(6)DOI:10.1093/rheumatology/keag285. PMID:42226006. IF:4.400(Q1/1D).

01/06/2026 Position statement on the pathological assessment of pancreatic resection specimens in pancreatic ductal adenocarcinoma by the Societat Catalana de Pàncrees and the Societat Catalana d'Anatomia Patologica

Salcedo-Allende, MT, Chimisana, VF, Llanos, ACZ, Piñol, TS, Freixas, MC, Sanz, IA, Ortiz, MR, Munoz, CM, Olivar, AA, Martos, RL, Gallego, AH, Hijos, MG, Fernández, MLD, Coma, MI, Muñoz, CG, Leal, CJB, Fumagalli, C, Szafranska, J, Borrego, MV, Cabús, SS, Piñas, JCF, Raya, ECV. Position statement on the pathological assessment of pancreatic resection specimens in pancreatic ductal adenocarcinoma by the Societat Catalana de Pàncrees and the Societat Catalana d'Anatomia Patologica. Gastroenterologia y Hepatologia. 2026; 49(6)DOI:10.1016/j.gastrohep.2026.502700. PMID:41655901. IF:1.900(Q3/7D).

01/06/2026 Who really benefits from chemotherapy in high-risk localized soft tissue sarcoma? A virtual twin analysis of ISG-STS 1001

Dossa, F, Callegaro, D, Palmerini, E, Quagliuolo, V, Martin-Broto, J, Grignani, G, Brunello, A, Blay, JY, Beveridge, RD, Ferraresi, V, Lugowska, IA, Pizzamiglio, S, Verderio, P, Palassini, E, Bianchi, G, Stacchiotti, S, Bague, S, Coindre, JM, Dei Tos, AP, Gronchi, A. Who really benefits from chemotherapy in high-risk localized soft tissue sarcoma? A virtual twin analysis of ISG-STS 1001. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11573. PMID:. IF:41.900(Q1/1D).

01/06/2026 Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies

Costa-Comellas, L, Monforte, M, Sanchez-Montañez, A, Romero-Duque, P, Pegoraro, E, Díaz-Manera, J, Vlodavets, D, Maggi, L, Moscatelli, M, DAmico, A, Olivé, M, Alonso-Pérez, J, Comi, G, Escudero-Fernández, JM, Urcuyo, GS, Pichiecchio, A, Berardinelli, A, Claeys, KG, Bruno, C, Panicucci, C, Bortolani, S, Torchia, E, Ricci, E, Monges, S, Bevilacqua, JA, Diaz-Jara, J, Walter, MC, Thiele, S, Lokken, N, Vissing, J, Quijano-Roy, S, Carlier, RY, Voermans, NC, Marini-Bettolo, C, Guglieri, M, Straub, V, Leonardis, L, Munell, F, Gómez-Andrés, D, Tasca, G. Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies. Annals of Clinical and Translational Neurology. 2026; 13(6)DOI:10.1002/acn3.70303. PMID:41475892. IF:3.900(Q1/3D).

01/06/2026 Patient-specific functional networks track early cognitive alterations and minor hallucinations in Parkinson's disease

Stampacchia, S, Bernasconi, F, Van De Ville, D, Amico, E, Kohoutová, L, Taylor, JP, Thomas, A, Pagonabarraga, J, Kulisevsky, J, Blanke, O. Patient-specific functional networks track early cognitive alterations and minor hallucinations in Parkinson's disease. Nature Mental Health. 2026; 4(6)DOI:10.1038/s44220-026-00657-x. PMID:. IF:(Q/D).

01/06/2026 Simple against advanced imaging for the selection of stroke therapy in the extended window (VESTA study)

Valls-Carbó, A, Millán, M, Castaño, C, De La Ossa, NP, Cardona, P, Flores, A, Biarnes, C, Boix, M, Urra, X, Terceño, M, Olivé-Gadea, M, Renom, PC, Rodríguez-Campello, A, Purroy, FF, Yugueros, B, Cánovas, D, Caamaño, IR, Beltrán-Mármol, B, Remollo, S, De Dios, M, Bashir, S, Aja, L, Gramegna, LL, Pastrana, M, Hernández-Pérez, M. Simple against advanced imaging for the selection of stroke therapy in the extended window (VESTA study). European Stroke Journal. 2026; 11(6)DOI:10.1093/esj/aakag068. PMID:42308555. IF:4.500(Q1/2D).

01/06/2026 GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

Cubala, WJ, Bajbouj, M, Bauer, M, Baune, BT, Cardoner, N, Devlin, F, Doolin, K, Herrero, RMD, Elices, M, Feeney, A, Galuszko-Wegielnik, M, Jakuszkowiak-Wojten, K, Janu, L, Kelly, JR, Ledden, K, Maclsaac, R, Madero, S, Mcinerney, SJ, Montejo, AL, Nawka, A, Pálenícek, T, Solà, VP, Ramaekers, JG, Reif, A, Ritter, P, Ryan, F, Svendsen, CB, Sweeney, C, Terwey, TH, Trivedi, MH, Valcheva, V, Vieta, E, Thase, ME. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026; 83(6)DOI:10.1001/jamapsychiatry.2026.0096. PMID:41879760. IF:17.100(Q1/1D).

01/06/2026 Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF (vol 30, pg 1025, 2024)

Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of three strategies of GvHD prophylaxis after T-cell replete haploidentical hematopoietic transplantation: Tacrolimus vs calcineurin inhibitors-MMF vs sirolimus-MMF (vol 30, pg 1025, 2024). Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2025.06.011. PMID:40516920. IF:4.400(Q1/1D).

01/06/2026 Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC

Fox, ML, Martínez, AP, Esquirol, A, Navarro, V, Cabirta, A, García-Cadenas, I, Almorox, RB, Fonseca-Santos, M, Fernando, IH, Bento, L, Raya, MP, Montoro, J, Calbacho, M, Ripa, TZ, Coll, CFI, Morales, RH, Ortí, G, Martino, R, González, PFC, López-Corral, L, Pérez-López, E, Navarro-Fernandez, J, Cascón, MJP, Sola, M, Catarineu, AT, Salamero, O, González, AP, Solano, C, Kwon, M, Valcárcel, D. Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC. Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2026.01.013. PMID:41534839. IF:4.400(Q1/1D).

01/06/2026 Combining three different pre-transplant scores improves predictive value in patients after haploidentical stem cell transplantation with TBF conditioning and PTCy (vol 27 , pg 614.e1 , 2021 )

Esquirol, A, Pascual, MJ, Garcia-Cadenas, I, Herruzo, B, Ferra, C, Torio, A, Torrent, A, Cuesta, M, Martino, R, Sierra, J. Combining three different pre-transplant scores improves predictive value in patients after haploidentical stem cell transplantation with TBF conditioning and PTCy (vol 27 , pg 614.e1 , 2021 ). Transplantation And Cellular Therapy. 2026; 32(6)DOI:10.1016/j.jtct.2025.06.010. PMID:40623446. IF:4.400(Q1/1D).

01/06/2026 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.

Powles, T, van der Heijden, MS, Bedke, J, Valderrama, BP, Kikuchi, E, Galsky, MD, Loriot, Y, Iyer, G, Yu, EY, Hoffman-Censits, J, Mar, N, Vulsteke, C, Sridhar, SS, Maroto-Rey, JP, Park, SH, Moreno, BH, Lichfield, J, Yu, XS, Wirtz, H, Gupta, S. Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.4507. PMID:. IF:41.900(Q1/1D).

01/06/2026 Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.

Portu, M, Sanz-Beltran, J, Pellicer, A, Navarro, B, Monleon, AR, Capdevila, P, Tallafigo, FL, Moran, T, Catot, S, Munoz, SP, Arriola, E, Sanchez, A, Osorio, K, Muñoz, A, Isla, D, Guarner, B, Piedra, A, Recio, SM, Barba, A, Majem, M. Prognostic factors and impact of concomitant medication in extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus anti-PD-L1: A Spanish multicenter real-world study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8107. PMID:. IF:41.900(Q1/1D).

01/06/2026 Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.

Forster, MD, Forget, F, Murillo, SM, García-Fructuoso, I, Ibrahim, NK, Marathe, O, Kristensen, CA, Laban, S, Metcalf, R, Majem, M, Peguero, JA, Wildiers, H, Marmé, F, Brana, I, Mueller, C, Brignone, C, Triebel, F. Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.2569. PMID:. IF:41.900(Q1/1D).

01/06/2026 Clinical impact and molecular profiling of PTEN loss and TMPRSS2:ERG fusion in metastatic hormone-sensitive prostate cancer.

Crous, C, de Herreros, MG, Torras, OR, Jimenez, N, Ferrer-Mileo, L, Garcia-Esteve, S, Rodriguez, L, Altamirano, M, Salinas, B, Cobo-Lopez, S, Fernandez-Mañas, L, Duran, MAC, Pous, AF, Chirivella, I, Figols, M, Costa, SC, Rodriguez-Vida, A, Anguera, G, González, NS, Mellado, B. Clinical impact and molecular profiling of PTEN loss and TMPRSS2:ERG fusion in metastatic hormone-sensitive prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5101. PMID:. IF:41.900(Q1/1D).

01/06/2026 Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).

Macia, S, Aladid, RL, Tovar, R, Garmendia, L, Lillo, CP, Fossati, M, Romero, ML, Selles, AN, Castellano, D, Gonzalezbilla, E, Maroto-Rey, JP, Piulats, JM, Lista, AGD, Parente, P. Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5129. PMID:. IF:41.900(Q1/1D).

01/06/2026 Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.

Alvarez, RMA, Hindi, N, Carrasco-Garcia, I, Sanfilippo, R, Sebio, A, Redondo, A, Alvarez, A, Morosi, C, Romagosa, C, Artigas, V, Casares, CM, Asencio, JM, Guzmán-Gómez, L, González-Lopez, J, Belinchon, B, Sangalli, C, Gutierrez, A, Jurado, JC, Broto, JM, Gronchi, A. Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11507. PMID:. IF:41.900(Q1/1D).

01/06/2026 Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens

Moura, DS, Mondaza-Hernandez, JL, Shirikova, A, Romero-Gonzalez, P, Carrera, M, Rodriguez, C, Martínez-Trufero, J, Sebio, A, Jurado, JC, Valverde, C, Beveridge, RD, Carrasco-Garcia, I, Gonzalez-Billalabeitia, E, Fernandez-Jara, J, Lopez-Jimenez, C, Hindi, N, Gutierrez, A, Broto, JM. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23526. PMID:. IF:41.900(Q1/1D).

01/06/2026 The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.

Gelderblom, H, Wang, V, Doherty, M, Sebio, A, Stacchiotti, S, Wilky, BA, Blay, JY, Brohl, AS, Morales, CMV, Reichardt, P, Martin-Broto, J, Davis, EJ, De Haan, JJ, O'Neill, B, Babcock, E, Garcia, J, Senne, L, Shepard, D, Chawla, SP, Jones, RL. The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11504. PMID:. IF:41.900(Q1/1D).

01/06/2026 Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.

Ferrer, L, Nadal, E, Dejean, T, Insa, A, Menu, P, Casal, J, Domine, M, Massuti, B, Majem, M, Martinez-Marti, A, Garcia-Campelo, R, Carpeño, JD, Cobo, M, Vivanco, GL, Morillo, ED, Bernabé, R, Vinolas, N, Barneto, I, Colin, T, Provencio, M. Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8022. PMID:. IF:41.900(Q1/1D).

01/06/2026 Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain

Pacheco-Barcia, V, Obispo, B, Tomas, E, de Torres, CS, Quintanar, T, Paez, D, Leon-Mateos, L, Cancio, H, Cortegoso, A, Anido, U, Quilez, A, Tarazona, N, Jimenez-Labaig, P, Sanchez-Martinez, DA, Goni, AS, Fernandez-Montes, A, Felip, E, Rodriguez, C, Elez, E. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04171-x. PMID:41436708. IF:2.500(Q3/6D).

01/06/2026 First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results

González-Lopez, J, Sebio, A, Broto, JM, Hindi, N, Villarejo-Campos, P, Jimenez, M, Díaz-Beveridge, R, Castellanos, JFO, Andajar, RL, Alvarez, RMA, Asencio, JM, Serrano, C, Conde, NR, Castro-Boix, S, Krauel, L, Colom, H, García, JAT, Lopera, E, Huguet, A, Campos, AP. First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23559. PMID:. IF:41.900(Q1/1D).

01/06/2026 Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).

Garrido, P, Villanueva, N, Bernabé, R, Campelo, RG, Sala, MA, Bote-de Cabo, H, Molla, MAI, Alvarez, R, Cruz, P, Majem, M, Santos, MAM, Cordero, MG, Rodriguez, JMO, Alvarez, RMA, Alvarez-Abril, B, Gutiérrez-Sainz, L, Gutiérrez, V, Munoz-Unceta, N, Felip, E, Isla, D. Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8092. PMID:. IF:41.900(Q1/1D).

01/06/2026 Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.

Broto, JM, Terés, R, Marquina, G, Perez-Fidalgo, JA, Lopez-Jimenez, C, Alonso-Romero, JL, Redondo, A, Gutierrez, A, Casado, A, Sebio, A, Ledesma, P, Merino-Garcia, JA, Mayordomo, E, Moura, DS, Hindi, N. Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11572. PMID:. IF:41.900(Q1/1D).

01/06/2026 Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial

Mondaza-Hernandez, JL, Moura, DS, Redondo, A, Sebio, A, Beveridge, RD, Martínez-Trufero, J, Romero-Gonzalez, P, Shirikova, A, Rodriguez, C, Carrera, M, Lopez-Jimenez, C, Hindi, N, Broto, JM. Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23520. PMID:. IF:41.900(Q1/1D).

01/06/2026 Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04164-w. PMID:41420791. IF:2.500(Q3/6D).

01/06/2026 Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).

Montañá, JR, Roselló, S, Paez, D, Safont, MJ, Vidal, J, Gravalos, C, Polo, E, Jimenez-Fonseca, P, Calle, SG, Paredes, BG, Beltran, M, Gonzalo-Ruiz, J, Rosales, C, Palmer, HG, Garcia, DL, Nuciforo, P, Vivancos-Prellezo, A, Tabernero, J, Elez, E. Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.TPS3681. PMID:. IF:41.900(Q1/1D).

01/06/2026 Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma

Martin-Broto, J, Martinez-Trufero, J, Diaz-Beveridge, R, Gutierrez, A, Carrasco, I, Lopez-Jimenez, C, Sebio, A, González-Billalabeitia, E, Ramos, R, Romagosa, C, Merino, J, Fernandez-Jara, J, Hernandez-Vargas, L, Garmendia, MD, Cruz-Jurado, J, Valverde, C, Mondaza-Hernandez, JL, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma. CLINICAL CANCER RESEARCH. 2026; 32(11)DOI:10.1158/1078-0432.CCR-26-0032. PMID:41817407. IF:10.200(Q1/1D).

01/06/2026 PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity

Aviles, P, Ribeiro, ML, Guillén, MJ, Martinez-Diez, M, Muñoz-Alonso, MJ, Santamaria-Nuñez, G, Torralba, D, Alamo, P, Gallardo, A, Oliva, MA, Mangues, R, Diaz, JF, Cuevas, C. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. MOLECULAR CANCER THERAPEUTICS. 2026; 25(6)DOI:10.1158/1535-7163.MCT-25-0559. PMID:41481906. IF:5.500(Q1/2D).

01/06/2026 Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation

Bartoletti, M, Del Turco, ER, Bussini, L, Paul, M, Sabik, EF, Castagna, A, Ripa, M, Gomes, MZR, Di Bella, S, Malosso, M, Lopez, AB, Franceschini, E, Bandera, A, Barbieri, V, Oliva, A, Munoz, P, Mularoni, A, Seminari, E, Morelli, P, Tascini, C, Papadimitriou-Olivgeris, M, Coppola, N, Cristini, F, Russo, A, Bassetti, M, Travi, G, Contreras, JL, Varisco, B, Viale, P, Cento, V, Gaibani, P, Bavaro, DF, Giannella, M. Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.018. PMID:41850617. IF:8.500(Q1/1D).

01/06/2026 Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study

Hornuss, D, Mathé, P, Giesen, R, Escolà-Vergé, L, Isler, B, Bartoletti, M, Lamy, B, Wagner, D, Kern, WV, Rieg, S. Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.006. PMID:41831716. IF:8.500(Q1/1D).

01/06/2026 Long-term Symptom, Psychological, and Functional Outcomes in Patients With Obstructive Sleep Apnea and Excessive Daytime Sleepiness Treated With Cpap: 24-month Results From the Hypnosa Cohort

Lázaro, AR, Mediano, O, Cano-Pumarega, I, Ruiz-Martínez, C, Cristeto, M, Agudo, MA, Lázaro, J, Bozalongo, LP, Vicente, P, Egea, C, Pía, C, Mora, JU, Sánchez, LP, Romero, S, Barrio, PR, Anon, MM, Barbe, F, Dolores, M, Peláez, CM, Podzamczer, I, Fortuna, AM, González, M, de Teran, TD, Dalmases, M, García, J, Alonso-Fernández, A, Bravo, MD, Cabriada-Nuño, V, Gajate, AU, Sanmartí, NG, Farrés, MM, Aguirre, MC, Salord, N, Fontanilles, E, Faus, CC, Pinedo, AR, Navas, IH, Gutiérrez, ML, Arcos, BA, Chinarro, BJ, Avalos, E, Carpi, MM, Perez, RC, Boukichou, N, De La Torre, MS. Long-term Symptom, Psychological, and Functional Outcomes in Patients With Obstructive Sleep Apnea and Excessive Daytime Sleepiness Treated With Cpap: 24-month Results From the Hypnosa Cohort. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2026; 212DOI:10.1093/ajrccm/aamag286.318. PMID:. IF:19.400(Q1/1D).

01/06/2026 Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease

Escolà-Gil, JC, Rotllan, N, Llorente-Cortes, V. Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease. SEMINARS IN CANCER BIOLOGY. 2026; 123DOI:10.1016/j.semcancer.2026.06.001. PMID:42248269. IF:15.700(Q1/1D).

01/06/2026 p19ARF deficiency disrupts lung and lipid homeostasis resembling the human alveolar proteinosis

Jiménez-Garcia, L, Pérez-Montero, A, Herranz, S, Luque, A, Tarín, C, Castillo, D, Lopez-Vilaro, L, Mariñas-Pardo, L, McCarthy, C, Acebo, P, Hortelano, S. p19ARF deficiency disrupts lung and lipid homeostasis resembling the human alveolar proteinosis. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY. 2026; 74(6)DOI:10.1093/ajrcmb/aanag003. PMID:41738246. IF:5.300(Q1/2D).

01/06/2026 An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration

Honey, MIJ, Hok-A-Hin, YS, Thijssen, EH, Cousins, KAQ, van der Weijden, B, In't Veld, L, Stoops, E, de Boer, SCM, Duits, FH, de Houwer, JFH, Morrema, THJ, Alcolea, D, Illán-Gala, I, Fortea, J, Lleó, A, Boxer, AL, Irwin, DJ, Lee, EB, Shaw, L, McMillan, CT, Wolk, DA, Hoozemans, JJM, van der Flier, WM, van der Ende, E, Seelaar, H, Verberk, IMW, Gan, L, Pijnenburg, Y, Teunissen, CE. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. NATURE MEDICINE. 2026; 32(6)DOI:10.1038/s41591-026-04341-6. PMID:41986736. IF:50.000(Q1/1D).

01/06/2026 Cerebrospinal fluid and plasma leptin dynamics following bariatric surgery in women

Pané, A, Videla, L, Viaplana, J, Ibarzabal, A, Molero, J, Moize, V, Lopez-Ruiz, S, de Hollanda, A, Ortega, E, Barroeta, I, Alcolea, D, Camacho, V, Vidal, J, Chiva-Blanch, G, Fortea, J, Jiménez, A. Cerebrospinal fluid and plasma leptin dynamics following bariatric surgery in women. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2026; 111(6)DOI:10.1210/clinem/dgaf702. PMID:41507035. IF:5.100(Q1/2D).

01/06/2026 How epigenetics impacts stroke risk and outcomes through DNA methylation: A systematic review

Gallego-Fabrega, C, Cullell, N, Fernández-Cadenas, I. How epigenetics impacts stroke risk and outcomes through DNA methylation: A systematic review. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2026; 46(6)DOI:10.1177/0271678X251322032. PMID:40012472. IF:4.500(Q1/2D).

01/06/2026 A Clinician View of the EMA Explanation of the Approval of Amyloid-Targeting Therapies

Jessen, F, Fortea, J. A Clinician View of the EMA Explanation of the Approval of Amyloid-Targeting Therapies. Lancet Regional Health-Europe. 2026; 65DOI:10.1016/j.lanepe.2026.101708. PMID:42180984. IF:13.000(Q1/1D).

01/06/2026 Integrating Planetary Health in Health Guidelines (GRADE Guidance 46)

Piggott, T, Saadat, P, Herrmann, A, Stein, AT, Darzi, AJ, Haines, A, Bognanni, A, Sousa-Pinto, B, Michels, C, Akl, EA, Poluzzi, E, Senerth, E, Madrid, E, Barbic, F, de'Donato, F, Nonino, F, Vist, GE, Neumann, I, Bracchiglione, J, Bousquet, J, Meerpohl, JJ, Antó, JM, Scahill, KA, Qiu, K, Miersch, K, Saif-Ur-Rahman, K, Thinagaran, LV, Benton, L, Schwingshackl, L, Siedler, MR, Bala, MM, Metzendorf, MI, Aloosh, M, Cinquini, M, Cumpston, M, Skoetz, N, Oloyede, O, Alonso-Coello, P, Dahm, P, Wang, Q, Vieira, RJ, Morgan, RL, Murthy, S, Hofstede, S, Laot-Cabon, S, Thomander, T, Siebert, U, Leontiadis, GI, Schünemann, H. Integrating Planetary Health in Health Guidelines (GRADE Guidance 46). ANNALS OF INTERNAL MEDICINE. 2026; 179(6)DOI:10.7326/ANNALS-25-04761. PMID:42114098. IF:15.200(Q1/1D).

01/06/2026 From reserve to the full spectrum of flow quantification in risk prediction

Flotats, A. From reserve to the full spectrum of flow quantification in risk prediction. European Heart Journal-Cardiovascular Imaging. 2026; 27(6)DOI:10.1093/ehjci/jeag063. PMID:41758618. IF:6.600(Q1/1D).

01/06/2026 Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure

Ortiz, A, Arici, M, Goumenos, DS, Adamczak, M, Eller, K, Ferreira, AC, Grandaliano, G, Jager, KJ, Lees, JS, Liakopoulos, V, Minutolo, R, Sezer, S, Azzolini, L, Fontana, M, Torres, F, Torra, R. Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2026; 41(6)DOI:10.1093/ndt/gfag007. PMID:41578941. IF:5.600(Q1/1D).

01/06/2026 Orthostatic blood pressure reduction is associated with renal damage in functionally preserved elderly hypertensive patients

Ramos-Galí, A, de la Sierra, A, Oliveras, A, Armario, P, Ayasreh, N, Arias, P, Vázquez, S, Camps, C, Castellanos, P, Calero, F, Fernández-Llama, P. Orthostatic blood pressure reduction is associated with renal damage in functionally preserved elderly hypertensive patients. NEFROLOGIA. 2026; 46(6)DOI:10.1016/j.nefro.2026.501521. PMID:42225512. IF:2.600(Q2/4D).

01/06/2026 Renal replacement therapies and adherence to EXTRIP consensus criteria in lithium poisoning: the multicenter SILITOX study

Pineda-Torcuato, A, Caballero-Bermejo, AF, Supervia, A, Salgado, E, O'Laoi, R, Sánchez, C, Córdoba, F, Farré, NR, Sanz-López, N, Ontiveros, HH, Sánchez, BAG, Gallardo, PR, Lobo-Antuña, V, Climent, B, Mora, S, Cózar-Llistó, A, Ortiz, MV, Urroz, M, Samper, VM, Román, PN, Suárez, XC, Moro, FJC, Kennedy, C, Jiménez, MDG, Gispert, MAA, Minguez, M, Sanmillán, IL, Cioccari, L, Pérez, BM, Garcia, SV, Gonzalo, JL, Burillo, G, Gutiérrez, E, Nogué-Xarau, S, Puiguriguer-Ferrando, J, Ruiz-Antorán, B. Renal replacement therapies and adherence to EXTRIP consensus criteria in lithium poisoning: the multicenter SILITOX study. EMERGENCIAS. 2026; 38(3)DOI:10.55633/s3me/040.2026. PMID:42345987. IF:6.300(Q1/1D).

01/06/2026 Analysis of comorbidity in an emergency department using diagnostic coding: The Elixhauser Index

Calvet-Pujol, A, Ris-Romeu, J, Albacar-Ingla, M, Vicente-Diez, F, Navarro-Arranz, P, Puig-Campmany, M. Analysis of comorbidity in an emergency department using diagnostic coding: The Elixhauser Index. EMERGENCIAS. 2026; 38(3)DOI:10.55633/s3me/018.2026. PMID:42345985. IF:6.300(Q1/1D).

01/06/2026 Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study

Vyvey, E, Soenen, R, Oon, HH, Mburu, S, Awici-Rasmussen, M, Affandi, AM, Gulliver, W, Choon, SE, Torres, T, Fitzgerald, A, Gonzalez-Cantero, A, López-Ferrer, A, Lee, CH, Valenzuela, F, Maul, J, Puig, L, Okuse, M, EL-Komy, M, Foley, P, Vender, R, Boehncke, W, Pohunek, J, Wang, YH, Londoño-García, A, Todd, G, Velasquez-Lopera, M, Lebwohl, M, Lau, E, Schmitt-Egenolf, M, Hilhorst, N, Connell, S, Deprez, E, Van Geel, N, Griffiths, C, van de Kerkhof, P, Lambert, J. Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2026; 40(6)DOI:10.1111/jdv.70313. PMID:41641893. IF:8.000(Q1/1D).

01/06/2026 Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma

Ferrándiz-Pulido, C, Gómez-Tomás, A, Siurana, S, Tortajada, C, Salido-Vallejo, R, Aguayo-Ortiz, RS, Amorós, IR, Turrión-Merino, L, Alvarez, BB, González, IP, Martí-Marti, I, Medrano-Martorell, S, Podlipnik, S, Mollet, J, Masferrer, E, Lopez-Castillo, D, Yébenes, M, Corbacho-Monné, M, Leal, L, Solano-López, A, Ruiz-Salas, V, Granell-Moreno, E, Alfonso, S, Mendoza, MD, Martínez-Domenech, A, Juárez-Dobjanschi, C, González, ES, Díaz, P, Toll, A. Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma. JAMA Dermatology. 2026; 162(6)DOI:10.1001/jamadermatol.2026.0803. PMID:42018290. IF:11.000(Q1/1D).

01/06/2026 Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review

de la Fuente, EG, Herrera, E, Esquerdo, IME, Sarró, DV, Figueras-Nart, I, Salvador, JFS, Gilaberte, Y, Alarcón, SS, Serra-Baldrich, E, Campos, MM, Moro, RM, Díaz-Cerezo, S, Moyano, S, Talavera-Rodríguez, I, Núñez, M. Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review. Dermatology and Therapy. 2026; 16(6)DOI:10.1007/s13555-026-01737-7. PMID:42014530. IF:4.200(Q1/1D).

01/06/2026 Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral

López-Ferrer, A, González-Cantero, A, Gutiérrez-Casbas, A, Martorell, A, Olveira, A, Madrid-Alvarez, MB, Nicolau, J, Carrascosa, JM, Baniandrés, O, Rivera, R, Ruiz-Villaverde, R, Queiro, R, de la Cueva, P. Multidisciplinary Management in Psoriasis: A Structured Approach for Early Comorbidity Detection and Referral. Dermatology and Therapy. 2026; 16(6)DOI:10.1007/s13555-026-01759-1. PMID:41999535. IF:4.200(Q1/1D).

01/06/2026 Chronic Venous Disease in Patients With Hidradenitis Suppurativa and Lymphedema: An Overlooked Problem

Garbayo-Salmons, P, Molina-Leyva, A, Aguayo-Ortiz, RS, Vilarrasa, E. Chronic Venous Disease in Patients With Hidradenitis Suppurativa and Lymphedema: An Overlooked Problem. Jeadv Clinical Practice. 2026; 5(2)DOI:10.1002/jvc2.70300. PMID:. IF:(Q/D).

01/06/2026 Durvalumab (D) in combination with BCG induction and maintenance (I plus M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.

De Santis, M, Shore, ND, Nishiyama, H, Krawczynski, M, Seyitkuliev, A, Guerrero-Ramos, F, Zukov, R, Kawahara, T, Goeman, L, Powles, T, Gust, KM, Feyerabend, S, Patel, M, Kulkarni, GS, Lebret, T, Westgeest, HM, Quartilho, A, Dabrowska, A, Marsh, A, Palou, J. Durvalumab (D) in combination with BCG induction and maintenance (I plus M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.4624. PMID:. IF:41.900(Q1/1D).

01/06/2026 Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study

Zaurito, P, Scilipoti, P, Longoni, M, de Angelis, M, Slusarczyk, A, Viti, A, Santangelo, A, Tremolada, G, Soria, F, Pradere, B, Krajewski, W, D'Andrea, D, Mari, A, Del Giudice, F, Pichler, R, Subiela, JD, Marcq, G, Gallioli, A, Afferi, L, Mastroianni, R, Simone, G, Albisinni, S, Mertens, LS, Laukhtina, E, Oberneder, K, Elena, JLR, Arandar, J, Puentedura, AL, Velascos, JC, Contieri, R, Hurle, R, Mori, K, Radziszewski, P, Shariat, SF, Gontero, P, Rouprêt, M, Montorsi, F, Salonia, A, Briganti, A, Moschini, M. Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2026; 44(6)DOI:10.1016/j.urolonc.2026.111089. PMID:41934021. IF:2.300(Q2/5D).

01/06/2026 The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin

Scilipoti, P, Zaurito, P, Longoni, M, Occhi, A, de Angelis, M, Disabato, N, Tremolada, G, Barracco, S, Slusarczyk, A, Soria, F, Krajewski, W, D'Andrea, D, Mari, A, Del Giudice, F, Pichler, R, Subiela, JD, Marcq, G, Gallioli, A, Afferi, L, Mastroianni, R, Simone, G, Albisinni, S, Mertens, LS, Laukhtina, E, Oberneder, K, Elena, JLR, Aranda, J, Puentedura, AL, Velasco, JC, Contieri, R, Hurle, R, Mori, K, Radziszewski, P, Shariat, SF, Gontero, P, Rouprêt, M, Pradere, B, Montorsi, F, Briganti, A, Moschini, M. The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2026; 44(6)DOI:10.1016/j.urolonc.2026.111085. PMID:41967989. IF:2.300(Q2/5D).

01/06/2026 A new machine learning model to predict novel trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy

Farré, A, Uleri, A, Gallioli, A, Baboudjian, M, Sanz, I, Casadevall, M, Hernández, P, Territo, A, Gavrilov, P, Faba, OR, Huguet, J, Gaya, JM, Palou, J, Breda, A. A new machine learning model to predict novel trifecta achievement and validation of its prognostic significance in a large single centre series of minimally invasive partial nephrectomy. Actas Urologicas Espanolas. 2026; 50(5)DOI:10.1016/j.acuro.2025.501900. PMID:41490536. IF:1.200(Q3/7D).

01/06/2026 Respiratory muscle activity and weaning from mechanical ventilation after spinal trauma: the ACCESSIT study

Schreiber, AF, Vieira, F, Madotto, F, Sousa, MLA, Rodrigues, A, Ko, MT, Phoophiboon, V, McFarlan, AW, Brault, C, Subirà, C, Singh, JM, Reid, WD, Rigamonti, A, Baker, A, Witiw, CD, Brochard, LJ. Respiratory muscle activity and weaning from mechanical ventilation after spinal trauma: the ACCESSIT study. Annals of the American Thoracic Society. 2026; 23(6)DOI:10.1093/annalsats/aaoag046. PMID:41723830. IF:5.400(Q1/2D).

01/06/2026 Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial

Gelber, PE, Ramírez-Bermejo, E, Caviasso, G, Juncosa-Chacón, J, Fariñas, O. Bone Marrow Aspirate Concentrate Improves the Early Osseous Integration of Fresh Osteochondral Allografts in the Knee: A Randomized Controlled Trial. AMERICAN JOURNAL OF SPORTS MEDICINE. 2026; 54(7)DOI:10.1177/03635465261437779. PMID:41992571. IF:4.500(Q1/1D).